MACK

Merrimack Pharmaceuticals to Present Preclinical Data on Bispecific Antibody MM-111 in ErbB2-Positive Gastric Cancers

[at noodls] – CAMBRIDGE, Mass., Jan. 23, 2013 (GLOBE NEWSWIRE) — Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) announced today that preclinical data regarding the bispecific antibody MM-111 will be presented at the … moreView todays social media effects on MACKView the latest stocks trending across Twitter. Click to view dashboardSee who Merrimack is hiring next, click here to view […]

Merrimack Pharmaceuticals Initiates Cross-Tumor Study to Investigate Potential Predictive Response Markers for a Developmental Nanotherapeutic Chemotherapy

[at noodls] – CAMBRIDGE, Mass., Dec. 19, 2012 (GLOBE NEWSWIRE) — Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced enrollment of its first patient in a cross indication translational study. The study is … moreView todays social media effects on MACKView the latest stocks trending across Twitter. Click to view dashboardSee who Merrimack is hiring next, click here to view […]

Merrimack Pharmaceuticals Initiates Phase 1 Clinical Study of MM-141 in Patients With Advanced Solid Tumors

[at noodls] – CAMBRIDGE, Mass., Dec. 12, 2012 (GLOBE NEWSWIRE) — Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced enrollment of its first patient in a Phase 1 clinical study of a novel compound for the … moreView todays social media effects on MACKView the latest stocks trending across Twitter. Click to view dashboardSee who Merrimack is hiring next, click here to […]

Merrimack Pharmaceuticals to Present at the 31st Annual J.P. Morgan Healthcare Conference

[at noodls] – CAMBRIDGE, Mass., Dec. 5, 2012 (GLOBE NEWSWIRE) — Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that Robert Mulroy, President & CEO, is scheduled to present at the 31st Annual J.P. Morgan … moreView todays social media effects on MACKView the latest stocks trending across Twitter. Click to view dashboardSee who Merrimack is hiring next, click here to view […]

Merrimack Pharmaceuticals to Present at the Oppenheimer 23rd Annual Healthcare Conference

[at noodls] – CAMBRIDGE, Mass., Dec. 3, 2012 (GLOBE NEWSWIRE) — Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that William Sullivan, CFO, is scheduled to present at the Oppenheimer 23rd Annual Healthcare … moreView todays social media effects on MACKView the latest stocks trending across Twitter. Click to view dashboardSee who Merrimack is hiring next, click here to view […]

Merrimack Pharmaceuticals To Present Phase I Data On MM-302 And Preclinical Data On Companion Diagnostics Both For The Treatment Of HER2-Positive Breast Cancer

[at noodls] – Research presented at 2012 SABCS examines cardiac safety profile of MM-302, a new HER2-targeted Liposomal Doxorubicin Agent….This is an abstract of the original noodl. To continue reading this document, … moreView todays social media effects on MACKView the latest stocks trending across Twitter. Click to view dashboard […]

Merrimack Pharmaceuticals to Present at the J.P. Morgan SMid Cap Conference

[at noodls] – CAMBRIDGE, Mass., Nov. 19, 2012 (GLOBE NEWSWIRE) — Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that Robert Mulroy, President & CEO, is scheduled to present at the J.P. Morgan SMid Cap … moreView todays social media effects on MACKView the latest stocks trending across Twitter. Click to view dashboard […]

Merrimack Pharmaceuticals to Present at Lazard Capital Markets’ 9th Annual Healthcare Conference

[at noodls] – CAMBRIDGE, Mass., Nov. 6, 2012 (GLOBE NEWSWIRE) — Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that William Sullivan, Chief Financial Officer, is scheduled to present at the Lazard Capital … moreView todays social media effects on MACKView the latest stocks trending across Twitter. Click to view dashboard […]